David Fuller
Chief Tech/Sci/R&D Officer at DIMERIX LIMITED
Net worth: 1 548 $ as of 29/04/2024
Profile
David Fuller is currently the Chairman of EpiAxis Therapeutics Pty Ltd.
He also holds the position of Non-Executive Director at AdAlta Ltd.
since 2020 and will be the Chief Medical Officer at Dimerix Ltd.
starting in 2023.
Previously, he was the Chief Medical Officer at Race Oncology Ltd.
from 2021 to 2022.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
RACE ONCOLOGY LTD.
0.00% | 29/06/2023 | 1,899 ( 0.00% ) | 1 548 $ | 29/04/2024 |
David Fuller active positions
| Companies | Position | Start |
|---|---|---|
| ADALTA LIMITED | Director/Board Member | 21/07/2020 |
| DIMERIX LIMITED | Chief Tech/Sci/R&D Officer | 22/10/2023 |
EpiAxis Therapeutics Pty Ltd.
 EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Chairman | - |
Former positions of David Fuller
| Companies | Position | End |
|---|---|---|
| RACE ONCOLOGY LIMITED | Chief Tech/Sci/R&D Officer | 10/11/2022 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| DIMERIX LIMITED | Health Technology |
| ADALTA LIMITED | Health Technology |
| RACE ONCOLOGY LIMITED | Health Technology |
| Private companies | 1 |
|---|---|
EpiAxis Therapeutics Pty Ltd.
EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Health Technology |
- Stock Market
- Insiders
- David Fuller
